OptimizeRx recently reported record net revenue in the third quarter of 2017, up 74% as compared to the same year-ago quarter, which was driven by growth in financial and brand messaging by new and returning clients. OptimizeRx expects the additional channel partner to enhance its reach, thereby supporting additional revenue growth.About Modernizing MedicineModernizing Medicine® and its affiliated companies are transforming how healthcare information is created, consumed and utilized in order to increase practice efficiency and improve patient outcomes. Our specialty-specific, data-driven and cloud-based electronic health records (EHR) and practice management (PM) systems, plus revenue cycle management (RCM) services, were built by a team including specialty physicians and practice management professionals. Our suite of products and services is designed to transform the clinical, financial and operational aspects of dermatology, gastroenterology, ophthalmology, orthopedics, otolaryngology, pain management, plastic surgery and urology practices. We also offer products designed specifically for ambulatory surgery centers. For more information, please visit www.modmed.com. Connect with Modernizing Medicine on our Blog, Facebook, LinkedIn and Twitter. About OptimizeRxOptimizeRx® (OTCQB:OPRX) is the nation's leading provider of digital health messaging via electronic health records (EHRs), providing a direct channel for pharma companies to communicate with healthcare providers. The company's cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information. The company's network is comprised of leading EHR platforms like Allscripts, Amazing Charts and Quest, and provides more than half a million healthcare providers access to these benefits within their workflow at the point of care. For more information, follow the company on Twitter, LinkedIn or visit www.optimizerx.com. Important Cautions Regarding Forward Looking StatementsThis press release contains forward-looking statements within the definition of Section 27A of the Securities Act of 1933, as amended and such section 21E of the Securities Act of 1934, amended. These forward-looking statements should not be used to make an investment decision. The words 'estimate,' 'possible' and 'seeking' and similar expressions identify forward-looking statements, which speak only as to the date the statement was made. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. IOS is a trademark or registered trademark of Cisco in the U.S. and other countries and is used under license by Apple, Inc. iPad is a registered trademark of Apple, Inc.
For more information, contact:Modernizing Medicine Tara Auclair Tel (561) 880-2998 x1321 firstname.lastname@example.org www.modmed.com MatterJessica WolterTel (978) email@example.com www.matternow.com OptimizeRx Contact:Doug Baker, CFOTel (248) 651-6568 firstname.lastname@example.org Investor Relations Contact for OptimizeRx:Ron Both, CMATel (949) email@example.com